Oriflame Announces Long-Term Strategic Manufacturing Partnership with Akums in India
NiveshIQ
NSE: AKUMS · Pharma
Akums Drugs and Pharmaceuticals Ltd.
₹664.55▲ ₹2.40 (+0.36%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on AKUMS. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Akums Drugs and Pharmaceuticals Ltd.
Akums Drugs and Pharmaceuticals Limited is a leading Indian pharmaceutical company that manufactures and sells a wide range of pharmaceutical products, including active pharmaceutical ingredients, excipients, and compounds. The company generates 79.95% of its turnover from pharma manufacturing and offers branded formulations in various therapeutic areas. With a strong presence in the Indian market, Akums operates as a pharmaceutical contract development and manufacturing company, catering to both domestic and international clients. The company has recently filed its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26 and has recommended a dividend of ₹3 per share. Despite facing cost pressures, Akums has maintained a strong technical position, reaching a 52-week high of
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹4,178 Cr +14.30% | ₹4,118 Cr -1.40% | ₹4,359 Cr +5.90% |
| EBITDA Margin | 2.94% | 11.27% | 14.93% |
| Net Profit | ₹2.00 Cr -98.00% | ₹344.00 Cr +17100.00% | ₹256.40 Cr -25.50% |
| EPS | ₹-0.29 | ₹21.74 | ₹16.67 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Oriflame Announces Long-Term Strategic Manufacturing Partnership with Akums in India
Oriflame Announces Long-Term Strategic Manufacturing Partnership with Akums in India
🔒
+ 3 more stories about Akums Drugs and Pharmaceuticals Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹1, 158 Cr, PAT ₹81 Cr, EPS ₹5.53, EBITDA margin 16.1%. Growth context: revenue YoY +9.6%, PAT YoY -45.8%, revenue QoQ -0.2%, PAT QoQ +19.6%. Street verdict: miss, revenue surprise +1.4%, PAT surprise -9.6%.
Patient volumes, occupancy, ARPOB/ARPO, case mix, and bed-capacity ramp-up remain the key forward drivers for the next 2...
FY26 (last completed FY): revenue ₹4, 359 Cr, PAT ₹256 Cr, EBITDA margin 14.9%, EPS ₹16.67. Year-on-year: revenue YoY +5...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for AKUMS
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track AKUMS alongside your other holdings
Unlock full AKUMS research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Akums Drugs and Pharmaceuticals Ltd.?
NiveshIQ detects active intelligence signals for Akums Drugs and Pharmaceuticals Ltd. (AKUMS) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Akums Drugs and Pharmaceuticals Ltd.?
Akums Drugs and Pharmaceuticals Ltd. operates in the Pharma sector with a market capitalisation of ₹786,868.1L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.